References
- Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–504
- Sullivan S, Ramsey S. The economic burden of COPD. Chest 2000;117:5S–9
- Rennard S. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest 1998;113 (Suppl):235S–41
- Feenstra TL, Van Genugten M, Hoogenveen R, et al. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Resp Crit Care Med 2001;164:590–6
- Rutten-van Molken M, Postma M, Joore M, et al. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999;93:779–87
- Tzanakis N, Anagnostopoulou U, Filaditaki V, et al. Prevalence of COPD in Greece. Chest 2004;125:892–900
- Oostenbrink JB, Rutten-van Molken M. Resource use and risk factors in high-source exacerbations of COPD. Respir Med 2004;98:883–91
- Andersson F, Borg S, Jansson S, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700–8
- Oostenbrink JB, Rutten-van Molken M, Monz B, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005;8:32–46
- Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399–404
- Donohue J, van Noord J, Bateman E, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or Salmeterol. Chest 2002;122:47–55
- Casaburi R, Mahler D, Jones P, et al. A long term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217–24
- Miravitilles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449–55
- Donaldson G, Seemungal T, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57: 846–52
- Friedman M, Menjoge S, Anton S, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with Chronic Obstructive Pulmonary Disorder (COPD). Pharmacoeconomics 2004;22:741–9
- Hilleman D, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of chronic obstructive pulmonary disease. Chest 2000;118:1278–85
- Oostenbrink J, Rutten-van Molken M, Al M, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004;23:241–9
- Van Hout B, Al MJ, Gordon G, et al. Costs, effects and C/E ratios alongside a clinical trial. Healt Econ 1994;3:309–19
- Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005;8:1–2